MolMed and TTY Biopharm entered into an exclusive agreement to commercialise Zalmoxis® in certain Asian territories
2017.6.30
最新消息
...
MolMed and TTY Biopharm entered into a term sheet to commercialise Zalmoxis® in certain Asian territories
2017.2.8
最新消息
...
Overcame Barriers- Anticancer Agent S-1 Capsule (S-1) Received Reimbursement for Treatment of Gastric Cancer
2016.12.13
最新消息
...
TTY Biopharm’s Anticancer Agent S-1 Received Reimbursement for Adjuvant Treatment of Locally-advanced Gastric Cancer
2016.12.13
最新消息
...
TTY Biopharm received an exclusive license from Taiho Pharmaceutical to sell an anticancer drug in Taiwan market
2016.10.18
最新消息
...
TTY Biopharm (4105 TT) and PharmaMar (MSE:PHM) jointly announce that PharmaMar submits Aplidin® for treatment of MM
2016.9.22
最新消息
...
TTY and the international company will jointly develop the overseas market for the Liposome product
2016.7.5
最新消息
...